A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer.
Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC) treated with Enzastaurin and Erlotinib live.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: enzastaurin
- drug: erlotinib
Eligibility
Inclusion Criteria:
1. Phase 1: Any incurable solid malignancy, with no more than 3 prior systemic treatment
regimens.
Phase 2: Histologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural
effusion or Stage IV per American Joint Committee on Cancer Staging Criteria for
NSCLC. Participants must have failed 1 or 2 prior systemic treatment regimen(s).
2. Performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG)
Scale
3. Prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and
the participant must have recovered from acute toxic effects (except alopecia) prior
to enrollment.
4. Prior radiotherapy is allowed to <25% of the bone marrow. Prior radiotherapy must be
completed at least 2 weeks before study enrollment, and the participant must have
recovered from acute toxic effects (except alopecia) prior to enrollment.
5. Non-measurable or measurable disease as defined by Response Evaluation Criteria in
Solid Tumors [RECIST, version (v) 1.0].
Exclusion Criteria:
Participants who
1. Are unable to swallow tablets.
2. Unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
3. Have previously been treated with an epidermal growth factor receptor (EGFR)
inhibitor, including erlotinib.
4. Are receiving concurrent administration of any other antitumor therapy.
5. Have received treatment within the last 30 days with a drug (not including study drug)
that has not received regulatory approval for any indication at the time of study
entry.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Melanie San Pedro-Salcedo
6507241388
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.